Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Who is a Christophe Degois ?

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on May 30, 2024 4:41pm

111 Views

Post# 36065193

RE:RE:RE:RE:RE:RE:RE:Who is a Christophe Degois ?

I thought his linkedin profile etc was actually fairly impressive. Works for a company which to me, aside from the technical and targeted approach they are focusing on......sounds like ONC. Would ONC award the options if an alliance, partnership or some agreement has not been consummated? There has to be something there

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec